[1] Wang R, Hong J, Liu R, et al. SFRP5 acts as a mature adipocyte marker but not as a regulator in adipogenesis[J].Mol Endocrinol, 2014, 53(3): 405~415. [2] Ouchi N, Higuchi A, Ohashi K, et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity[J]. Science, 2010, 329(5990): 454~457. [3] Miyoshi T, Doi M, Usui S, et al. Low serum level of secreted frizzled-related protein 5, an anti-inflammatory adipokine, is associated with coronary artery disease[J]. Atherosclerosis, 2014, 233(2): 454~459. [4] Wang X, Peng Q, Jiang F, et al. Secreted frizzled-related protein 5 protects against oxidative stress-induced apoptosis in human aortic endothelial cells via downregulation of Bax[J].Biochem Mol Toxicol, 2017(1): e21978. [5] Albataineh MM, Kinlough CL, Poland PA, et al. Muc1 enhances the beta-catenin protective pathway during ischemia-reperfusion injury[J]. Ajp Renal Physiology, 2016, 310(6): 569~579. [6] Teliewubai J, Bai B, Zhou Y, et al. Association of asymptomatic target organ damage with secreted frizzled related protein 5 in the elderly: the Northern Shanghai Study[J]. Clin Interv Aging, 2018, 13: 389~395. [7] Cho YK, Kang YM, Lee SE, et al. Effect of SFRP5 (secreted frizzled-related protein 5) on the WNT5A (wingless-type family member 5A)-induced endothelial dysfunction and its relevance with arterial stiffness in human subjects[J]. ArteriosclerThrombVasc Biol, 2018, 38(6): 1358~1367. [8] Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease[J]. Eur Heart Fail, 2014, 35(27): 1782~1791. [9] Nakamura K, Sano S, Fuster JJ, et al. Secreted frizzled-related protein 5 diminishes cardiac inflammation and protects the heart from ischemia/reperfusion injury[J].Biol Chem, 2016, 291(6): 2566~2575. [10] Bie Z, Sun L, Geng C, et al. MiR‐125b regulates SFRP5 expression to promote growth and activation of cardiac fibroblasts[J]. Cell Biol Int, 2016, 40(11): 1224~1234. [11] Chatani N, Kamada Y, Kizu T, et al. Secreted frizzled-related protein 5 (Sfrp5) decreases hepatic stellate cell activation and liver fibrosis[J]. Liver Int, 2015, 35(8):2017~2026. [12] 金鑫, 郭炳彦,李拥军.分泌型卷曲相关蛋白5和N末端B型利钠肽原与慢性心力衰竭的相关性研究[J].河北医科大学学报,2017,38(12):1365~1368. [13] Finley SD, Popel AS. Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions[J].Natl Cancer I, 2013, 105(11): 802~811. [14] Kikuchi R, Nakamura K, Maclauchlan S, et al. An anti-angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease[J]. Nat Med, 2014, 20(12): 1464~1471. [15] Schulte DM, Müller N, Neumann K, et al. Pro-inflammatory wnt5a and anti-inflammatory sFRP5 are differentially regulated by nutritional factors in obese human subjects[J]. Plos One, 2012, 7(2): e32437. [16] Wright WS, Longo KA, Dolinsky VW, et al. Wnt10b inhibits obesity in ob/ob and agouti mice[J]. Diabetes, 2007, 56(2): 295~303. [17] Harte AL, Mcternan PG, Mcternan CL, et al. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes[J]. Diabetes ObesMetab, 2010, 5(5): 302~310.
2019, Vol. 25 
冀公网安备13080202000677号